• AI in Healthcare: How To Assess What Works

    Feb 18 | Bio-IT World| At a panel discussion this week at the ViVE conference in Nashville, Tenn., researchers and physicians discussed the promise and hype of AI. Moderated by Alexander Morgan, partner at Khosla Ventures, the discussion was wide ranging and discussed the AI tools ready for use by physicians; which classes of AI are not yet delivering; and how to assess what’s right for you. More

  • Ultima Genomics Sequencing Platform Selected for UK Biobank Study

    Feb 14 | Bio-IT World| Last month, Ultima Genomics announced that their UG 100 sequencing platform was selected by UK Biobank to be used in their human proteomics study, which is anticipated to be the largest and most comprehensive proteomics study to date. The study is intended to quantify more than 5,400 protein markers across 600,000 samples, which will help researchers understand how protein levels fluctuate over time and how these changes correlate with disease progression and aging. More

  • Epigenetics Alone Can Alter Cancer Susceptibility

    Feb 13 | Bio-IT World| Evidence is emerging that epigenetic differences prior to birth can signal the type of cancer that occurs decades later by dictating which mutated cells turn into a tumor. It is “underappreciated” that most otherwise healthy people are walking around with cancer-causing mutations that their body suppresses unless their built-in defense system mysteriously fails. More

  • Lifebit, Psifas Partner for Israeli Genomic Medicine Initiative

    Feb 10 | Bio-IT World | On the heels of its announced collaboration with 23andMe, Lifebit, has announced a long-term partnership with Psifas, Israeli Genomic Medicine Initiative. This collaboration will empower groundbreaking advancements in personalized medicine by providing a secure and unified platform for clinical-genomic research across Israel’s diverse population. More

  • Crystal Ball: At JP Morgan, Companies Predict Trump Administration Impacts

    Feb 06 | Bio-IT World| Market questions always arise with the changing of presidential administration in the United States, though this year’s uncertainty seems a bit heightened. Expected outlooks to NIH funding and other regulatory and even Department of Government Efficiencies (DOGE) changes came up in analyst questions after some of the presentations at the J.P. Morgan Healthcare Conference last month. More

  • 10X Genomics at JPM: New Products, New Sales Team, New Markets

    Feb 05 | Bio-IT World | 10X Genomics launched a spate of new products in 2024 in both their single cell and spatial areas. “Our view is that eventually, every relevant sample will need to be analyzed with single cell and spatial context,” said Serge Saxonov, 10X CEO and co-founder, in his 2025 J.P. Morgan Healthcare Conference presentation. More

  • Recursion at JPM: Exscientia Merger and the Coming Virtual Cell

    Feb 04 | Bio-IT World | Chris Gibson, CEO of Recursion, gave the company update last month at the 2025 J.P. Morgan Healthcare Conference. Gibson gave updates on several Recursion pipeline programs for indications including precision oncology, rare disease, and other indications. He also gave updates on the merger with Exscientia and the coming virtual cell. More

  • Redefining Storage to Enable Digital Twins

    Jan 30 | Bio-IT World | While the concept of digital twins is similar in life sciences to manufacturing, human bodies are significantly more complex than industrial machines and systems, amplifying the challenges surrounding data generation, management, and analysis. Making effective use of the data required to advance digital twin research creates immense infrastructure challenges. More

  • Follow the Money: Obesity, COPD, Universal AI for Biology

    Jan 29 | Bio-IT World | January saw new company launches in COPD and small molecules, as well as investments targeting genetic engineering, epigenome editing, regenerative medicine, and more. More

  • GSK’s $1B Acquisition, Roche Licenses Gene Therapy, New Products, More

    Jan 28 | Bio-IT World | 23andMe launches a new research offering after mass resignation by their board, new multi-omics tool from Enhanc3D Genomics, Absci and Owkin announce an AI partnership, a new cloud-based vivarium platform from Charles River, and more. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!